DOCSLIB.ORG

ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021 ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021 Company Ticker CUSIP Shares Market Value($) Weight(%) 1 TELADOC HEALTH INC TDOC 87918A105 3,937,797 531,208,815.30 6.99 2 EXACT SCIENCES CORP EXAS 30063P105 3,971,013 381,296,668.26 5.01 3 PACIFIC BIOSCIENCES OF CALIF PACB 69404D108 13,696,148 350,347,465.84 4.61 4 VERTEX PHARMACEUTICALS INC VRTX 92532F100 1,722,281 316,228,014.41 4.16 5 FATE THERAPEUTICS INC FATE 31189P102 4,825,395 312,926,865.75 4.12 6 IONIS PHARMACEUTICALS INC IONS 462222100 8,572,965 310,341,333.00 4.08 7 REGENERON PHARMACEUTICALS REGN 75886F107 430,742 275,201,063.80 3.62 8 TWIST BIOSCIENCE CORP TWST 90184D100 2,237,350 250,829,308.50 3.30 9 TAKEDA PHARMACEUTIC-SP ADR TAK UN 874060205 13,592,076 229,570,163.64 3.02 10 ACCOLADE INC ACCD 00437E102 5,268,242 226,850,500.52 2.98 11 INTELLIA THERAPEUTICS INC NTLA 45826J105 1,508,421 224,965,907.94 2.96 12 VEEVA SYSTEMS INC-CLASS A VEEV 922475108 741,198 222,307,516.14 2.92 13 CAREDX INC CDNA 14167L103 3,433,475 220,978,451.00 2.91 14 CRISPR THERAPEUTICS AG CRSP H17182108 1,804,041 210,044,493.63 2.76 15 INCYTE CORP INCY 45337C102 2,893,385 199,643,565.00 2.63 16 INVITAE CORP NVTA 46185L103 6,059,066 182,135,523.96 2.40 17 ADAPTIVE BIOTECHNOLOGIES ADPT 00650F109 4,888,391 178,377,387.59 2.35 18 BEAM THERAPEUTICS INC BEAM 07373V105 1,849,698 175,110,909.66 2.30 19 SIGNIFY HEALTH INC -CLASS A SGFY 82671G100 8,107,683 160,937,507.55 2.12 20 UIPATH INC - CLASS A PATH 90364P105 2,955,628 155,761,595.60 2.05 21 CASTLE BIOSCIENCES INC CSTL 14843C105 2,130,211 154,312,484.84 2.03 22 CODEXIS INC CDXS 192005106 5,921,779 151,419,889.03 1.99 23 IOVANCE BIOTHERAPEUTICS INC IOVA 462260100 5,941,379 148,296,819.84 1.95 24 SCHRODINGER INC SDGR 80810D103 2,541,038 147,253,152.10 1.94 25 ARCTURUS THERAPEUTICS HOLDIN ARCT UQ 03969T109 2,544,563 129,034,789.73 1.70 26 GINKGO BIOWORKS HOLDINGS INC DNA 37611X100 9,355,762 117,882,601.20 1.55 27 PERSONALIS INC PSNL 71535D106 5,175,029 101,637,569.56 1.34 28 PFIZER INC PFE 717081103 2,232,656 98,102,904.64 1.29 29 10X GENOMICS INC-CLASS A TXG 88025U109 635,050 97,899,308.00 1.29 30 VERACYTE INC VCYT 92337F107 1,988,462 97,196,022.56 1.28 31 908 DEVICES INC MASS 65443P102 2,680,342 97,510,841.96 1.28 32 QUANTUM-SI INC QSI 74765K105 9,756,089 85,951,144.09 1.13 33 BERKELEY LIGHTS INC BLI 084310101 3,904,528 83,634,989.76 1.10 34 REPARE THERAPEUTICS INC RPTX 760273102 2,986,708 82,522,742.04 1.09 35 BUTTERFLY NETWORK INC BFLY 124155102 7,241,695 82,844,990.80 1.09 36 SEMA4 HOLDINGS CORP SMFR 81663L101 9,676,742 78,962,214.72 1.04 37 1LIFE HEALTHCARE INC ONEM 68269G107 3,613,877 77,517,661.65 1.02 38 EDITAS MEDICINE INC EDIT 28106W103 1,276,014 74,914,781.94 0.99 39 RECURSION PHARMACEUTICALS-A RXRX 75629V104 2,612,259 64,052,590.68 0.84 40 SOMALOGIC INC SLGC 83444K105 4,866,047 62,139,420.19 0.82 41 VERVE THERAPEUTICS INC VERV 92539P101 1,276,133 61,165,054.69 0.80 42 CELLECTIS - ADR CLLS 15117K103 3,884,479 52,090,863.39 0.69 43 ZYMERGEN INC ZY 98985X100 3,807,510 51,020,634.00 0.67 44 PALANTIR TECHNOLOGIES INC-A PLTR 69608A108 1,640,902 46,864,161.12 0.62 45 NANOSTRING TECHNOLOGIES INC NSTG 63009R109 872,609 43,394,845.57 0.57 46 NOVARTIS AG-SPONSORED ADR NVS 66987V109 445,620 36,955,266.60 0.49 47 CERUS CORP CERS 157085101 5,243,005 34,498,972.90 0.45 48 SURFACE ONCOLOGY INC SURF 86877M209 4,284,470 31,705,078.00 0.42 49 AQUABOUNTY TECHNOLOGIES AQB 03842K200 6,274,782 25,789,354.02 0.34 50 COMPUGEN LTD CGEN M25722105 3,678,563 22,880,661.86 0.30 51 DYNAMICS SPECIAL PURPOSE C-A DYNS 268010105 2,301,832 22,742,100.16 0.30 52 CARIBOU BIOSCIENCES INC CRBU 142038108 426,842 10,346,650.08 0.14 53 EVOGENE LTD EVGN M4119S104 2,963,362 8,356,680.84 0.11 54 DREYFUS GOVT CASH MAN INS X9USDDGCM 5,714,009 5,714,009.44 0.08 55 ORGANOVO HOLDINGS INC ONVO 68620A203 246,104 1,730,111.12 0.02 56 BRISTOL-MYERS SQUIBB CO BMY 110122108 612 36,860.76 0.00 57 CM LIFE SCIENCES II -CW27 SLGCW 83444K113 548,744 0.00 0.00 The principal risks of investing in ARK ETFs include equity, market, management and non-diversification risks, as well as fluctuations in market value and net asset value ("NAV"). Investors should carefully consider the investment objectives and risks as well as charges and expenses of an ETF before investing. This and other information are contained in each ETF's prospectus, which may be obtained by contacting the ETF's transfer agent The Bank of New York Mellon or by clicking here. Please read the prospectus carefully before you invest. The market price of ETF shares may differ significantly from their NAV during periods of market volatility. ETF shares may only be redeemed directly with the ETF at NAV by Authorized Participants, in very large creation units. Holdings are subject to change without notice and are not a recommendation to buy or sell any security. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns. ©2021, ARK Investment Management LLC. All content is original and has been researched and produced by ARK Investment Management LLC unless otherwise stated. No part of this content may be reproduced in any form, or referred to in any other publication, without the express written permission of ARK Investment Management LLC. All statements made regarding companies, securities or other financial information on this site or any sites or articles relating to ARK Investment Management LLC are strictly beliefs and points of view held by ARK Investment Management and are subject to change without notice. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed. This material has been distributed for informational purposes only and should not be considered as investment advice or a recommendation of any particular security, strategy or investment product..
Load more

Recommended publications
  • Telaprevir (Incivek)
    © Hepatitis C Online PDF created September 25, 2021, 4:19 pm Telaprevir (Incivek) Discontinued. This treatment has been discontinued. Table of Contents Telaprevir Incivek Summary Drug Summary Adverse Effects Class and Mechanism Manufacturer for United States FDA Status Indications Dosing Clinical Use Cost and Medication Access Resistance Key Drug Interactions Full Prescribing Information Figures Drug Summary Although telaprevir was a promising direct-acting antiviral agent that had impact in the hepatitis C treatment field during 2011 to 2013, it was subsequently replaced by newer direct-acting antiviral agents that were more effective, better tolerated, and more convenient. Based on the dwindling role of telaprevir after newer direct-acting antiviral agents were approved, Vertex pharmaceuticals discontinued the sales and distribution of telaprevir in the United States in October 2014. Telaprevir does have some current importance since persons who previously failed a telaprevir-based regimen may have developed resistant associated variants, which could potentially impact subsequent therapy. Adverse Effects The most significant adverse effects reported in the main registration trials and in post-marketing experience were rash, anorectal complaints, and anemia. When comparing triple therapy of telaprevir, peginterferon, and ribavirin with dual therapy of peginterferon and ribavirin alone significant differences were noted with rash (56% versus 34%), anemia (36% versus 17%), and anorectal complaints that include anorectal discomfort, anal pruritus, and hemorrhoids (29% versus 7%). In most cases, the rash that develops is eczematous or maculopapular in character and mild to moderate in severity; the rash is typically manageable with good skin care and topical emollients or corticosteroids. In some instances, however, telaprevir has caused serious skin Page 1/5 rashes, including Steven's Johnson Syndrome (SJS), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Toxic Epidermal Necrolysis (TEN).
    [Show full text]
  • Objectives & Accreditation
    Objectives & Accreditation ACTIVITY FORMAT Live TARGET AUDIENCE This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management. TYPE OF ACTIVITY Live Activity; Application/ Knowledge EDUCATIONAL OBJECTIVES At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide appropriate care and counsel for patients and their families. At the conclusion of this activity, all participants should be able to: Session I: The Impact of Genetics in Lipidology? Apply insight from human population genetics studies to identify novel therapeutic targets for a better understanding for atherosclerotic cardiovascular disease. Describe the current and future technologies available for genetic screen includinghow to apply them in clinical practice both for diagnosis and risk assessment Discuss experimental techniques in development for genetic manipulation to target inherited lipid disorders Keynote I Discuss ApoC3 as both a risk factor for ASCVD and as potential for therapeutic manipulation Session II- Focus on Lipoprotein (a) Discuss the epidemiology of Lipoprotein(a) (LP(a)) for both thrombosis and ASCVD Discuss the pathophysiology of LP(a) and how this impacts increased risk of ASCVD and thrombosis Discuss the status of current and emerging treatment options targeting LP(a) Clinical Lipidology Track- Critically appraise emerging research
    [Show full text]
  • Pioneering New Markets Changing the Standard of Care
    ANNUAL 2020 REPORT Pioneering New Markets Changing the Standard of Care UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 2855 Gazelle Court, Carlsbad, CA 92010 (Address of Principal Executive Offices) (Zip Code) 760-931-9200 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol Name of each exchange on which registered Common Stock, $.001 Par Value ‘‘IONS’’ The Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No □ Indicate by check if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes □ No ☒ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Vertex Pharmaceuticals Global Medical Affairs Pharmd Fellowship Program 2020 Message from Global Medical Affairs Leadership
    Vertex Pharmaceuticals Global Medical Affairs PharmD Fellowship Program 2020 Message from Global Medical Affairs Leadership Dear Candidates, Vertex Pharmaceuticals in collaboration with Northeastern University is privileged to host and expand the PharmD Fellowship Program. We are excited to work with our fellows as integral members of our team and facilitate in-depth exposure to a range of functional areas, offering them the critical opportunity to gain extensive experience in the biopharmaceutical industry. In addition to fostering each individual’s personal and professional growth, the program’s primary goal is to extend the visibility of valuable contributions that a Doctor of Pharmacy can bring to the pharmaceutical industry. At Vertex, our Global Medical Affairs fellows are highly encouraged to take on immersive projects, allowing them to work across departments with leaders in the industry. We advocate for them to partake in truly unique, impactful work that develops their skills, sparks curiosity, and drives the science. Vertex’s open and innovative culture allows the fellows to ask questions, challenge the status quo, and explore their interests across multiple expertise areas. As a pharmacist, I am extremely proud of the establishment of the Vertex PharmD Fellowship program in Global Medical Affairs and excited to welcome our future fellows. Vertex is an ideal place for fellows to start their professional career, and we are dedicated to the development of the next generation of pharmacist leaders in the biopharmaceutical industry. As Vertex continues to grow and evolve into a company in multiple disease areas, I am confident that our fellows will be an essential part of moving the needle to deliver on our commitment to patients.
    [Show full text]
  • United States Securities and Exchange Commission Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2020 INTELLIA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37766 36-4785571 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (857) 285-6200 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Trading Name of each exchange Title of each class Symbol(s) on which registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    [Show full text]
  • United States Securities and Exchange Commission Form
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2005 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS 000-19319 04-3039129 (State or other jurisdiction of (Commission File Number) (IRS Employer Identification incorporation) No.) 130 Waverly Street Cambridge, Massachusetts 02139 (Address of principal executive offices) (Zip Code) (617) 444-6100 Registrant’s telephone number, including area code: Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 8.01. Other Events. On June 17, 2005, Vertex Pharmaceuticals Incorporated and Merck & Co., Inc. issued a joint press release that announced the initiation of an additional Phase I study with VX-680, a small molecule inhibitor of Aurora kinases. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 9.01.
    [Show full text]
  • October 2019
    J.P. Morgan Healthcare Conference Presented by Brett P. Monia, Ph.D. Chief Executive Officer January 15, 2020 Forward Looking Language Statement This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of SPINRAZA® (nusinersen), TEGSEDI™ (inotersen), WAYLIVRA™ (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' majority owned affiliate. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2018, and its most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of this and other documents are available at www.ionispharma.com. In this presentation, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and its subsidiaries.
    [Show full text]
  • *Attending Companies (As of 1.29.19) 3E Therapeutics CLINICAL
    *Attending Companies (As of 1.29.19) 3E Therapeutics CLINICAL NETWORK SERVICES 5AM Ventures CoSec Consulting AbbVie Daiichi-Sankyo Adastra Pharmaceuticals DCLSA ADYA Decoy Biosystems Alcami Corporation Deloitte Consulting, LLP Algomedix DNA Ink AlivaMab Discovery Services Donnelley Financial Solutions Allergan Drug Delivery Experts Amgen EcoR1 Capital, LLC Amgen EnduRx Pharmaceuticals Inc. Aristea Therapeutics Entos Pharmaceuticals Arivale EPL Archives LLC Aspect Biosystems Ltd Equillium Astellas Venture Management Esperion Axcelead Drug Discovery Partners FERRER INTERNACIONAL, SA Bay City Capital Forge Therapeutics Bayer FreeMind BCN Biosciences Gemseki Inc. Beacon Discovery, Inc. Genentech Boehringer Ingelheim GigaGen Boehringer Ingelheim GigaMune BriOri BioTech Gilead Sciences Bristol-Myers Squibb Global Source Ventures Calibr Glysantis Inc. CeleCor Therapeutics Gossamer Bio Cell Care Therapeutics Halloran Consulting Group Cellgen Diagnostics Halozyme Therapeutics CILcare Hamamatsu Pharma Research USA, Inc. Cipla Technologies LLC Illumina Ventures Illumina, Inc. OrPro Therapeutics, Inc. Immune Biosolutions Otonomy Inevitable Ventures Otsuka America Pharmaceuticals Ionis Pharmaceuticals Pattern Pharma Japan Bioindustry Association Pfenex JCR USA, Inc. Phoenix Molecular Designs Kalgene Pisces Therapeutics Illumina, Inc. Pivotal bioVenture Partners Immune Biosolutions Prevencio, Inc. Inevitable Ventures PrimeVax Immuno-Oncology, Inc. Ionis Pharmaceuticals Qpex Biopharma Japan Bioindustry Association Recordati Rare Disease JCR USA, Inc.
    [Show full text]
  • Customer Margins for Onechicago Futures
    #XXXXX TO: ALL CLEARING MEMBERS DATE: August 13, 2018 SUBJECT: Customer Margins for OneChicago Futures On a monthly basis OCC updates OneChicago scan ranges used in the OCX SPAN parameter file. The frequency of the updates is intended to keep the futures customer margin rates more closely aligned with clearing margins, while maintaining regulatory minimums related to security futures. This month’s new rates will be effective on Tuesday 8/21. To receive email notification of these rate changes, which includes an attached file of the rate changes, please subscribe to the ONE Updates list from the OFRA webpage: https://www.theocc.com/risk- management/ofra/ The following scan ranges will be updated and all others will not change: Commodity Name Current Scan Code Scan Range Range Effective 8/21/2018 AAN Aarons Inc 23.0 24.2 AAP ADVANCED AUTO PARTS INCCOM 22.0 24.9 AAXN Axon Enterprise, Inc. 25.2 32.8 ABBV Abbvie Inc. 21.4 20.0 ABC AMERISOURCEBERGEN CORP 20.0 22.5 ABX BARRICK GOLD CORP 20.0 24.3 ACAD ACADIA PHARMACEUTICALS 31.5 42.1 ACH ALUMINUM CORP CHINA LTDSPON ADR H SHS 21.1 24.0 AEGN Aegion Corp 22.0 25.2 AEM Agnico Eagle Mines Limited 20.0 21.1 AEO AMERICAN EAGLE OUTFITTERS NECOM 20.0 21.2 AFSI AMTRUST FINANCIAL SERVICES ICOM 30.2 35.1 AGIO AGIOS PHARMACEUTICALS INCCOM 30.7 33.7 AGX ARGAN INCCOM 27.3 35.7 AKAM AKAMAI TECHNOLOGIES INCCOM 20.0 22.1 AKRX AKORN INCCOM 38.2 40.7 AKS AK STL HLDG CORP 34.3 38.0 ALKS Alkermes plc 27.4 39.1 ALNY ALNYLAM PHARMACEUTICALS INCCOM 46.5 54.1 ALXN ALEXION PHARMACEUTICALS INC 21.1 22.8 AMAG AMAG Pharmaceuticals Inc 34.4 43.6 AMBA AMBARELLA INCSHS 27.7 32.5 AMD ADVANCED MICRO DEVICES INC 31.7 34.5 AMED AMEDISYS INCCOM 21.9 24.2 AMN AMN HEALTHCARE SERVICES INCCOM 23.2 26.1 AMWD AMERICAN WOODMARK CORPCOM 40.4 26.9 ANET ARISTA NETWORKS INCCOM 24.7 28.3 ANF ABERCROMBIE & FITCH CO 34.8 38.9 AOBC American Outdoor Brands Corporation 22.7 24.6 APEI AMERICAN PUBLIC EDUCATION INCOM 37.0 40.8 APOG APOGEE ENTERPRISES INCCOM 20.0 23.0 ARCO ARCOS DORADOS HOLDINGS INC 22.4 24.4 ATGE Adtalem Global Education Inc.
    [Show full text]
  • Questions About CRISPR
    CRISPR Questions about CRISPR A huge industry will grow from its innovation, but the IP environment around CRISPR is far from established. Marc Döring and Daniel Lim investigate The discovery of the potential of CRISPR and its first Cas system for various applications. characterisation in the form of the CRISPR/Cas9 system One group comprises Intellia, Caribou Biosciences (Caribou), represents a true revolution in the life sciences field. It is best Caribou founder Jennifer Doudna and the University of California, known as a method that allows for the accurate and targeted cutting Berkeley (UCB). That group is broadly aligned with CRISPR Tx, ERS of DNA to enable editing of genes, but variants can accomplish a Genomics and its founder Emmanuelle Charpentier, who collaborated wide range of other extremely useful effects, including modulation of with Doudna and co-owner of UCB’s foundational CRISPR patents. On gene expression. The power and versatility of the system has opened 16 December 2016, the Doudna and Charpentier camps formalised the door to advances in a wide range of industries, including human their alliance, signing a global cross-licensing and patent prosecution therapeutics, animal health, agriculture and bioindustry. CRISPR has the co-operation agreement. potential to revolutionise any industry in which molecular biology and Opposing them is Editas, its founder Feng Zhang and the Broad genetic technology play a part. Institute of MIT and Harvard (the Broad), who hold a separate, However, despite the clear potential of the technology, and leaving competing portfolio of foundational CRISPR/Cas9 patents. aside the significant amount of research and development still to be These spin-out companies have wasted no time in partnering undertaken, question marks linger over the legal and regulatory position variously with big pharma, venture capitalists and fellow disruptive of CRISPR technology and CRISPR-based products.
    [Show full text]
  • Biopharma Leaders Join Trump and Thunberg in Davos
    No. 3989 January 31, 2020 again a key theme at Davos, and many biopharma executives are joining the con- versation this year. These include Werner Baumann, CEO of Bayer, who spoke on a panel on 21 Janu- ary about ‘When Humankind Overrides Evolution,’ focusing on gene-editing tech- nologies for use in agriculture, food and medicine. Meanwhile Takeda CEO Chris- tophe Weber joins a discussion on shap- ing the future of health and healthcare systems on 22 January. Speaking on the gene-editing panel, Baumann said there was “less and less trust in society for the advances of tech- nology,” adding that “the only way to get beyond it is that we do a better job in terms of explaining what we are doing.” Bayer is working with CRISPR Thera- peutics on CRISPR/Cas9 gene-editing in hemophilia, ophthalmology and autoim- Biopharma Leaders Join Trump mune diseases, but also has a major stake in genetically modified seeds via its Mon- And Thunberg In Davos santo division. He called for absolute transparency ANDREW MCCONAGHIE [email protected] from corporations and governments on gene-editing technology, but also decried fter focusing on the year ahead tive to plant 1 trillion trees, an effort aimed the previous “insane dominance” that anti- in biopharma business at the J.P. at soaking up rising levels of carbon diox- GM crop campaigners have been allowed AMorgan conference in San Fran- ide in the atmosphere. to wield. cisco last week, the sector’s attention has 17-year-old environmental campaigner Others taking part include Stéphane switched to the World Economic Forum in Greta Thunberg made her own address to Bancel, Moderna Therapeutics’ chief exec- Davos, Switzerland from 21-24 January.
    [Show full text]
  • Pax Large Cap Fund USD 7/31/2021 Port
    Pax Large Cap Fund USD 7/31/2021 Port. Ending Market Value Portfolio Weight Microsoft Corporation 89,240,649.84 6.2 Apple Inc. 56,474,074.80 3.9 Alphabet Inc. Class A 45,168,406.39 3.1 Applied Materials, Inc. 40,802,748.42 2.8 United Parcel Service, Inc. Class B 40,145,031.68 2.8 Amazon.com, Inc. 40,024,252.52 2.8 Procter & Gamble Company 38,175,527.61 2.6 Alphabet Inc. Class C 37,288,542.96 2.6 T-Mobile US, Inc. 36,913,478.16 2.5 CVS Health Corporation 35,823,305.60 2.5 Bristol-Myers Squibb Company 35,683,263.33 2.5 Trane Technologies plc 34,492,144.83 2.4 Voya Financial, Inc. 34,364,677.20 2.4 Fiserv, Inc. 33,109,434.63 2.3 Medtronic Plc 32,631,060.24 2.2 Lowe's Companies, Inc. 32,345,328.78 2.2 JPMorgan Chase & Co. 31,275,786.80 2.2 salesforce.com, inc. 31,164,938.74 2.1 Aptiv PLC 30,049,685.00 2.1 Target Corporation 29,624,476.10 2.0 Becton, Dickinson and Company 29,334,525.00 2.0 Citizens Financial Group, Inc. 28,825,635.20 2.0 Merck & Co., Inc. 28,216,517.16 1.9 BlackRock, Inc. 28,142,268.01 1.9 Vertex Pharmaceuticals Incorporated 26,265,874.00 1.8 Lincoln National Corporation 25,842,318.84 1.8 Sysco Corporation 25,428,711.00 1.8 Equinix, Inc.
    [Show full text]